Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
Study Identifier
OG09002
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Results Available
Protocol
Available Language(s): English
Statistical Analysis Plan
Available Language(s): English
Plain Language Summary
Available Language(s): English
Study Details
Medical Condition
Study Drug
Phase
Phase 4
Sex
Female & Male
Age
3 - 16 Years
Protocol Summary
This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition. Children will be treated with 0.75 g of gel/day for two weeks. Patients will then return to the clinic for a potential dose titration. At this time their dose may be adjusted up to 1g/day, down to 0.5g/day, or remain the same at 0.75g of gel/day depending on the individual response and tolerability. The total treatment time is 14 weeks and total time on the study is 16 weeks.
Study Locations
Location
Status
Location
Loma Linda University /ID# 236889
Loma Linda, California, United States, 92354
Status
Not applicable
Location
Child Hosp of Orange County,CA /ID# 237517
Orange, California, United States, 92868
Status
Not applicable
Location
Children's Hospital Colorado - Aurora /ID# 237620
Aurora, Colorado, United States, 80045
Status
Not applicable
Location
Augusta University Medical Center /ID# 238188
Augusta, Georgia, United States, 30912-0004
Status
Not applicable
Location
University of Mississippi Medical Center /ID# 238065
Jackson, Mississippi, United States, 39216-4500
Status
Not applicable
Location
Albany Medical College /ID# 236880
Albany, New York, United States, 12208
Status
Not applicable
Showing {first} - {last} of {total} Results